Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) surged 25.82% to $9.6 in the after-hours session following the reports that it has entered into a non-exclusive distribution agreement with Gabriel Science, LLC for the sale of Microcyn Technology products into the dental market and it has already taken its first order.
Sonoma manufactures Endocyn, a Microcyn Technology product, a biocompatible root canal irrigant that is non-staining for teeth or restorations. According to a study published in the Journal of Endodontics, Regenerative Endodontics by the Departments of Endodontics at Louisiana State University School of Dentistry, Endocyn showed less toxicity than sodium hypochlorite.
The full study can be found here: https://www.sciencedirect.com/science/article/abs/pii/S0099239917310439
Dr. Mark Fontenot, the managing member at Gabriel Science, LLC, said, “we believe Endocyn and the Microcyn family of products are the next generations of hypochlorous acid products that can assist in the treatment of a diverse range of dental, head and neck conditions.”
Amy Trombly, CEO of Sonoma Pharmaceuticals, said, “This is an exciting development in dental technology on our part, to expand our offerings of Microcyn-powered dental products available in the U.S. market.”